paid. The cost savings from non-transplanted livers were equally impressive even at the discounted price of £30,000 per transplant. Are we to believe that these spare livers would not be used for some equally deserving cases thus resulting in no net saving to the health service? As a paediatrician I remain unconvinced by the arguments advanced that a national screening programme at two weeks after delivery will solve this clinical dilemma.

T MATTHEWS. The Children's Hospital. Temple St. Dublin 1. Republic of Ireland


Professor Mowat and Dr Dick comment: We are please to have Professor Matthew's support in trying to achieve surgical treatment for all infants with biliary atresia by 60 days of age. Because we share some of the concerns he expresses, we do not advocate screening for biliary atresia but selective screening or more correctly case finding by detecting conjugated hyperbilirubinemia in jaundiced infants and then to detect all forms of hepatobiliary disease. Many will have other hepatobiliary disorders for which early and specific treatment is desirable. By screening at the same time as the infant is being assessed by community health care professionals much of the cost and logistic difficulties will be minimised.

King's Healthcare Trust is undoubtedly in the real world. Next year the cost for a direct bilirubin will increase to £4.00 including all overheads! Since last year our infant aged 18 days with biliary atresia was 'overlooked' by a member of our junior staff. The total serum bilirubin concentration was 72 μmol/l. We cannot stress strongly the infant with biliary atresia in the first weeks of life appears well. The only constant abnormal clinical feature is jaundice which may be very mild and urine which is persistently yellow and pigmented. In the last two years 25 infants and children in UK died while on waiting lists for liver transplantation. If any of these were alive because a selective screening made transplantation unnecessary for one child with biliary atresia, would any paediatrician object?

Because the optimum time for screening is controversial, community staff in our district are testing for conjugated hyperbilirubinaemia in jaundiced infants of different ethnic backgrounds. This study funded by the Children's Liver Disease Foundation will clarify logistical difficulties and the prevalence of benign jaundice in the third and fourth week after birth.

Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine

EDITOR.—Now and then the concept 'abdominal migraine' appears in the literature as if it were a fact. I have always been reluctant to accept it as a special entity. The only thing that distinguishes it from recurrent abdominal pain in Apley's definition is the exclusion of the milder cases. The demonstration of a special visual evoked response pattern in children with migraine and abdominal migraine is of course interesting.

But it is necessary to do this test in an unselected group of children with recurrent abdominal pain, to see if it delimits a special group among these children, or if it is a common phenomenon in children with recurrent abdominal pain. Even if it should delimit a special group it might just be a question of severity.

I am not able to refute the existence of abdominal migraine. But until now nothing except severity seems to justify the concept. Migraine in a close family member is a prerequisite for the diagnosis of abdominal migraine. But not even this criterion seems to be of any help, as accumulation of several kinds of presumed psychosomatic symptoms including headache is very common in children with recurrent abdominal pain and in their families. I would still prefer the expression recurrent abdominal pain for all bellyachers, at least until we know more about aetiology and pathogenesis.

These reflections should be seen as a comment on the paper of Symon and Russell showing effect of pizotifen in children with abdominal migraine. It is of course important to show that pizotifen does work. But the paper gives rise to two important questions. How does pizotifen work on all children with recurrent abdominal pain? And does the effect of pizotifen in a group of children with severe pain justify the migraine diagnosis?

Aetiology of recurrent abdominal pain is not certain, but it is likely that psychosomatic mechanisms are operative. In the complex pathogenesis different peptide and motility may be important factors. It is in this context that the effect of pizotifen should be considered.

MOGENS FJORD CHRISTENSEN. Department of Pediatrics. Herning Central Hospital. 7400 Herning. Denmark


Dr Symon and Dr Russell comment: Recurrent abdominal pain is a symptom and not a diagnosis. We find no difficulty in accepting that children with recurrent headaches may be suffering from a wide variety of different diseases, including migraine, tension headaches, and even cerebral tumours. Similarly recurrent abdominal pain may be the final symptom of a wide variety of disease processes. In our practice the commonest cause of recurrent abdominal pain is constipation. The concept that all recurrent abdominal pain is psychosomatic in origin has been discredited by the absence of any statistically significant differences between children with recurrent abdominal pain and pain free children with regard to various psychological variables thought to be associated with psychogenicity.

The children whom we treated in our trial were not 'bellyachers', but were suffering from recurrent severe disabling symptoms. Unlike bellyachers their symptoms came in discrete attacks with complete normality between episodes. We accept that the term 'abdominal migraine' is not however a diagnostic term, however the arguments for this were fully rehearsed in a recent clinical controversies article.2 Perhaps there would be fewer objections if the syndrome had a different epithet, such as Buchanán's syndrome, as some people wish to reserve the term migraine solely for headaches on the basis of its presumed etiological derivation from heredismia.

We would not expect pizotifen to be of benefit in all children with recurrent abdominal pain and logically we feel that it is unlikely that pizotifen would be of value in recurrent abdominal pain other than abdominal migraine. We are not aware of any trials of the use of pizotifen in recurrent abdominal pain other than our own trial in abdominal migraine.

To lump together all children with recurrent abdominal pain as having psychosomatic pathology is to do grave disservice to those patients who come to us seeking relief of their symptoms.


Medicalisation of the normal variant—treatment of the short, sexually immature adolescent boy

EDITOR.—I enjoyed Christopher Kelner's annotation but as a non-endocrinologist am unhappy about his advice for delayed puberty in the absence of disease that "boys over 14 years of age ... who have impaired self image and social withdrawal not responding to reassurance" should be considered for treatment. But, "should not be denied when appropriate".

There are two issues. Firstly the widespread use of potent endocrine agents for a non-disease entity, and secondly whether or not there will be no long term adverse effects during the lifetime of the individuals concerned or, indeed, of their progeny? Patients need to know whether they want to take the risks and doctors need to be accountable.

Strean Leon, the president of the Australian Medical Association, in considering the unexpected long term consequences of another endocrine intervention, Creutzfeldt-Jakob Disease. The prospect of permanent gross dwarfism probably, even in retrospect, justified the, at the time unpredictable and thus unquantifiable, long term risk. Does the transient and common phenomenon of delayed puberty? We must surely include permanence as well as severity and incidence in any therapeutic cost benefit analysis.

Secondly, and more importantly, we need to be careful, as paediatricians, not to narrow the range of accepted normality and to medicalise normal variation. A teenager with delayed puberty may have impaired self image and social withdrawal at the age of 15. Where is the evidence that short term manipulation of the situation with drugs is of long term benefit to the psychological health of the future man, quite apart from its implications for decision making?